Livanova

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products. The Neuromodulation segment designs, develops, and markets Neuromodulation therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression (DTD), and obstructive sleep apnea. The company was founded in 1987 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LivaNova reports solid Q4 earnings, eyes growth amidst industry challenges

LivaNova's Q4 2022 showcased revenue growth and operational resilience amid challenges. With a strong cash position and strategic focus, the company aims for continued growth in 2023. Managing inflation, supply chain issues, and debt levels will be crucial for sustained success.

Livanova reports robust Q1 earnings, eyes growth amid market recovery

Livanova's Q1 2023 showcased strong revenue growth driven by Cardiopulmonary and Neuromodulation segments, with strategic initiatives progressing well.
While facing challenges in ACS revenue and epilepsy monitoring trends, the company remains focused on patient care and innovation.
Opportunities lie in market recovery, international business growth, and continued progress in strategic initiatives for future expansion.
Overall, Livanova's performance reflects resilience, adaptability, and a commitment to driving shareholder value creation.

LivaNova reports strong Q2 revenue growth and strategic initiatives progress

LivaNova's Q2 2023 earnings call highlighted robust revenue growth, improved margins, and strategic initiatives driving positive momentum. While facing legal challenges and patient access issues, the company is investing in core business growth and innovation for future opportunities.

LivaNova reports strong Q3 results, eyes growth amid leadership transition

LivaNova's Q3 2023 performance showcased revenue growth, margin expansion, and increased earnings per share, underpinned by operational efficiency.
While facing challenges in cost management and leadership transition, the company is poised for growth with opportunities in segment performance and margin improvement.
Increased guidance for full-year 2023 reflects confidence in future prospects, with a focus on product launches and clinical study progress.
Anticipated tax rate changes and the need for successful volume scaling present considerations for future financial planning and operational execution.

LivaNova reports strong Q4 growth, eyes revenue expansion in 2024

LivaNova's Q4 2023 performance showed revenue growth, margin impact from cybersecurity incident, and positive guidance for 2024.
The company's strengths lie in segment reorganization, income improvement prospects, and strategic focus on growth areas.
Challenges include cybersecurity disruptions, legal uncertainties, tax rate fluctuations, and unaccounted stock-based compensation impacts.
Opportunities in revenue growth, product expansion, international market penetration, and strategic planning with new leadership are key focus areas.

LivaNova reports robust Q1 earnings, eyes growth through innovation

LivaNova's Q1 performance reflects a solid start to 2024, driven by revenue growth and strong financial metrics. The company's strategic focus on innovation, clinical studies, and disciplined growth strategies positions it well for future success in the healthcare market.

LivaNova reports strong Q2 earnings, eyes growth through strategic focus

LivaNova's Q2 2024 earnings call highlighted robust financial performance, strategic imperatives, and revised guidance. The company aims to capitalize on its strengths in cardiopulmonary and epilepsy businesses while addressing challenges in litigation and expenses. Opportunities for growth are evident through revised guidance and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.

LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels.

LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced Vladimir Makatsaria, CEO, will present a general business update during fireside chats at Stifel, Wolfe and Piper in New York.

LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock?

The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2%

Frontdoor Inc.

Kura Sushi USA

KRUS, FTDR and LIVN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 7, 2024.

Best Momentum Stocks to Buy for November 7th

Emergent BioSolutions

Moody's

MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024.

New Strong Buy Stocks for November 7th

Nordstrom

JWN and LIVN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2024.

Best Value Stocks to Buy for November 7th

LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Anthony Petrone - Mizuho Mike Matson - Needham & Company Matt Miksic - Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Third Quarter 2024 Earnings Conference Call. My name is Lydia, and I'll be your operator today.

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript

LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago.

LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance.

LivaNova Reports Third-Quarter 2024 Results

LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth.

LivaNova: Economics Should Start Making Sustained Improvements

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its Board of Directors has appointed Susan Podlogar to the Board, effective October 8, 2024.

LivaNova Appoints Susan Podlogar as a New Director

Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks.

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024.

LivaNova to Announce Third-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced Vladimir Makatsaria, CEO, will present in a fireside chat at the Baird 2024 Conference in NYC at 10:15 am ET on Sept. 10.

LivaNova to Present at the Baird Global Healthcare Conference

LivaNova PLC (NASDAQ:LIVN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria – Chief Executive Officer Alex Shvartsburg – Chief Financial Officer Ahmet Tezel – Chief Innovation Officer Conference Call Participants Rick Wise – Stifel Mike Sarcone – Jefferies Michael Polark – Wolfe Research Adam Maeder – Piper Sandler Anthony Petrone – Mizuho Group Mike Matson – Needham & Company David Rescott – Baird Matt Miksic – Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Second Quarter 2024 Earnings Conference Call. My name is Emily, and I'll be moderating your call today.

LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript

LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago.

LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.

LivaNova Reports Second-Quarter 2024 Results

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ:LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN

OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach.

Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To list.

LivaNova to Announce Second-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced preliminary results for the unipolar cohort of the RECOVER study, assessing use of VNS Therapy in treatment-resistant depression.

LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova announced Vladimir Makatsaria, CEO, will present a fireside chat at the Goldman Sachs Conference in Miami, Florida at 1:20 pm ET on June 10.

News for Livanova Stock (LIVN)